Following an abandoned collaboration agreement between a complex peptide formulator and a generic manufacturer, CRA was retained to support an academic senior consultant in the ensuing arbitration. CRA’s team examined lost profit damages for the formulator, examining uptake and pricing of the specialty drug with an orphan drug indication. The matter ultimately settled.
2022 Year in Review: Litigation
Our return to office in 2022 coincided with a year of intense activity in our dispute resolution engagements and other areas of the practice. Wins at trial...